Fastforward Innovations Investors - FFWD

Fastforward Innovations Investors - FFWD

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Fastforward Innovations Limited FFWD London Ordinary Share GG00BRK9BQ81 ORD 1P
  Price Change Price Change % Stock Price Last Trade
0.10 1.21% 8.35 16:13:09
Open Price Low Price High Price Close Price Previous Close
8.25 8.25 8.35 8.35 8.25
more quote information »
Industry Sector

Top Investor Posts

888icb: I have a suggestion for Ed and the FFWD board to address the problem of the share trading at a large discount to NAV and to reward long term investors. FFWD should commit now to returning a proportion of the profit received from the sale of Leap Gaming to Shareholders by way of a special dividend. If he wants any help with this Jim Mellon has used special dividends in companies set up like FFWD with several investments.
dillondon1: Listen I’ll give you a lesson in currently valuing an entity (NAV relative to SP) such as FFWD. The only NAV figures that should be taken into consideration are the listed entities and the cash they hold. This gives a figure of X that you can compare to Y share price This gives you a baseline to then look at each unlisted investment individually and price each unit up. You can use the following..development of the company since initial investment, time scales for IPO, management changes, names of new investors in further funding rounds,changing legislation, values of listed competitors, size of current ongoing funding rounds (what effect this will have on valuation etc) You cannot use a blunt tool such as NAV IS 11p share price is 8p therefore conclude that NAV is 18p so share price will also follow suit and be 15p. It’s complex and involves thinking as you may well end up paying for more than it’s worth or selling for a fraction of near term value that you haven’t realised is there in plain sight.
rickyl1: To be honest, if you base your investing/trading on something an anonymous guy says on the Internet then you'll learn some lessons pretty quickly and probably painfully. I just don't get the obsession with doggo and the other guys but it's sometimes mildly amusing but mostly tedious. Night night fellow gamblers/investors/traders :)
burtond1: Looking for a fund of funds in Medicinal Cannabis? Then look into @ffwdinnovations and get all this and more." #FFWD intriguing set of holdings opens a door for private investors into the somewhat exclusive early stage #cannabis & biotechnology sectors"
888icb: I think we will see the large increases in market cap this year because we have now reached the time for liquidity events in our early investments. Ed mentioned the 2 main drivers of the market cap and he knows what Leap should produce as he has all the accounting information as a Director of Leap. I think it is very useful to understand the history of FFWD as this gives further confidence in why I think it will deliver a good return. FFWD was set up by Jim Mellon inspired by his book of the same name to invest in companies at pre ipo stages not available to normal private investors. So you need people like Jim Mellon and high net worth investors who have access to those opportunities. Look at who our large shareholders are and look at their involvement as Directors and large shareholders in the companies FFWD has invested in. They will all make more money the sale of the underlying investments but will also want to make a return on the money they have had invested for years many at considerably higher share prices than today’s. In the early days the 2 main drivers were Jim Mellon and Lorne Abony both of whom were Directors. Over time both resigned as Directors to concentrate on the underlying investments which have all performed very well. But I also suspect they both resigned to avoid the potential conflicts of interests inherent in being Directors of the Investee companies as well as FFWD. So we then have Ed’s arrival on the scene and we are aware of his links to Lorne. So while Ed doesn’t have any shares himself there are a number of large shareholders who he won’t want to disappoint. Everything points to Leap delivering this year and with a 44% stake the lions share of the profits have to come to FFWD to put the original large shareholders into profit.
gordan ghetto: This is the cannabis stock to be in ANA - will be producing 200 TONS !!! 50% shares held by 4 people 30% by BOD £6m mkt cap Share price 1.1p hTTps:// hTTps://
dave4545: Seems volumes are rapidly improving today for Yooma. Maybe Yooma can be our version of Rms, start of stuck around a certain level then it takes off once those in from the start have took their profits and sold out, always takes a few days for new investors to clear out pre Ipo investors.
the skipper: Well put Dave. I hope anyone looking in here as a consequence of the write up this evening on Proactive Investors will take note. hTTps://
888icb: UP 9.3% on volume of 350000 and 22 trades. Good to see today’s RNS which reminds us we have some serious investors holding big chunks of the company. They have stuck with the company despite large falls in the value of their holdings. They understand the investments that FFWD has made and have been prepared to wait for them to come good. We are now at that point where a number of investments are very close to liquidity events. These long term investors will have paid 15p and higher I think in the case of today’s RNS investor. These investors will need the share price to be well above 25p to even see a half decent return on their investment but will have invested expecting a lot more from these early stage investments. It is looking very promising and one hopes today’s rise is evidence that the market is starting to take notice.
dillondon1: Brief synopsis of Longevity Week Words are from a Longevity CEO who was present I was recently in London for the Longevity Week, a collection of single day and evening events organized by investor Jim Mellon of Juvenescence and supporting groups. Varied events focused separately on (a) educating investors in the science of aging, (b) generating a larger investment community for the new longevity industry, and (c) improving the non-profit world and its efforts to explain the merits of treating aging to the public, to bring therapies to the clinic, and to improve the state of older life using presently available tools. Jim Mellon clearly understands that building an industry focused on the medical control of aging, particularly in regions where medical development and clinical practice is so very heavily regulated, requires raising the water level when it comes to understanding of that industry and its potential. The first event, the Science Summit, was a small and selective gathering that I was kindly invited to. It was the successor to an earlier master class on the science of aging organized for an audience of investors interested in the field, based on the concept that investors, and then the field as a whole, will benefit from a better understanding of the underlying science. I should say that these are largely investors in funds rather than investors in companies, occupying the higher valuation end of the investment community. These are people who, collectively as a class, have a lot of influence over the shape and pace of development of future industries through their choices in what to invest in. The second event, Investing in the Age of Longevity, was a part of the investor-focused programs organized by Jim Mellon's Master Investor organization, a way to promote understanding of - and participation in - the longevity industry among the members of the broader investor community. This is of course of great benefit to Juvenescence, cofounded by Jim Mellon, but it is also of great benefit to everyone else. If we are to see this industry thrive and deliver on the promise of treating aging as a medical condition, it absolutely must be promoted and made interesting to the investment community. The final event was the yearly Longevity Forum, in which the focus is on non-profits, governments, and the process of explaining the promise of treating aging as a medical condition to society at large. Alongside the three days of events were evening gatherings of folk in the longevity community, a chance to catch up with people who are working on interesting projects, or funding those interesting projects. Much of the more important networking happens outside the events, as is ever the case. It was an interesting week, all told, and it is clear that we're all going to be very much better off in the years ahead as a result of the efforts of Jim Mellon and his allies and staff. This is a step up in the scale of advocacy for the treatment of aging in comparison to past years.
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210518 05:11:57